Evaluation of [18F]PSMA-1007 uptake variability in patients with prostate cancer
Background: The biodistribution of PSMA-ligands is of interest in radionuclide therapy planning. We investigated the variability of [18F]PSMA-1007 uptake in organs at risk and in relation to tumour burden in prostate cancer patients. Methods: A total of 1086 patients who underwent PSMA PET-CT for staging or recurrence of prostate cancer were included. Total lesion volume (TLV) and total lesion upt
